Claims
- 1. A composition for inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction comprising an effective amount of a compound having the structural formula ##STR54## and including all stereoisomers thereof; wherein
- A and B may be the same or different and A is CH.dbd.CH or (CH.sub.2).sub.2,
- B is CH.dbd.CH, C.dbd.C, or (CH.sub.2).sub.2 ; m is 1 to 8;
- X is OH; ##STR55## CO.sub.2 R.sup.1 wherein R.sup.1 is H or lower alkyl; or ##STR56## wherein Z is H, lower alkyl, or aryl, SO.sub.2 --Q (wherein Q is lower alkyl or aryl), ##STR57## or OR.sup.2 wherein R.sup.2 is H; Y is aryl-lower alkyl; alkenyl containing 3 to 6 carbons; alkynyl containing 3 to 6 carbons; pyridyl, pyridyl-lower alkyl; pyridyl containing one or two halogen or lower alkyl substituents; thienyl; thienylalkyl; thienyl containing one or two halogen or lower alkyl substituents; cycloalkyl; cycloalkyl containing one or two halogen, lower alkyl or lower alkoxy groups on the ring; cycloalkylalkyl, cycloalkylalkyl containing one or two halogen, lower alkyl or lower alkoxy groups on the ring; or phenoxymethyl; wherein lower alkyl or alkyl by itself or as part of another group contains 1 to 12 carbons, aryl by itself or as part of another group contains 6 to 10 carbons in the ring portion, and cycloalkyl by itself or as part of another group contains 3 to 12 carbons in the ring portion;
- and represents a single bond or double bond with the proviso that where represents a double bond, A is CH.dbd.CH and B is CH.dbd.CH or (CH.sub.2).sub.2 and Y is other than alkenyl or alkynyl or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.
- 2. The composition as defined in claim 1 wherein X in said compound is CO.sub.2 R.sup.1, ##STR58## and wherein Q is phenyl or lower alkyl.
- 3. The composition as defined in claim 1 wherein Y in said compound is phenyl-alkyl, thienyl-alkyl, cycloalkyl, or cycloalkylalkyl.
- 4. The composition as defined in claim 1 wherein Y is ##STR59##
- 5. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.beta.(5Z),3.alpha.(1E, 3S*),4.beta.]-7-[3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or [1.beta.,2.beta.(5Z), 3.alpha.(1E, 3R*), 4.beta.]-7-[3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 6. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.beta.(5Z), 3.alpha.(1E, 3S*), 4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-butenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or [1.beta.,2.beta.(5Z), 3.alpha.(1E, 3R*), 4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-butenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 7. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.beta.(5Z), 3.alpha.(1E, 3S*), 4.beta.]-7-[-3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
- 8. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.beta.(5Z), 3.alpha.(1E, 3S*),4.beta.]-7-[3-(4-cyclohexyl-3-hydroxy-1-butenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or [1.beta.,2.beta.(5Z), 3.alpha.(1E, 3R*), 4.beta.]-7-[3-(4-cyclohexyl-3-hydroxy-1-butenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 9. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.beta.(5Z), 3.alpha.(1E,3S*),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-butenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or its methyl ester.
- 10. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.beta.(5Z), 3.alpha.(1E, 3.alpha.,4.alpha.),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (fast moving isomer A): [1.beta.,2.alpha.(5Z),3.alpha.(1E, 3.alpha.,4.beta.)4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (fast moving isomer B); or [1.beta.,2.alpha.(5Z), 3.alpha.(1E, 3.beta.),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (slow moving isomer) or methyl esters of each.
- 11. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.alpha.(5Z), 3.alpha.(1E, 3.alpha.),4.beta.]-7-[3-[3-hydroxy-4-(2-methylphenyl)-1-butenyl]-7-oxabicyclo[2.2.1]hept-.sub.2 -yl]-5-heptenoic acid (fast movlng isomer) or [1.beta.,2.alpha.(5Z), 3.alpha.(1E, 3.beta.), 4.beta.]-7-[3-[3-hydroxy-4-(2-methylphenyl)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (slow moving isomer) or methyl esters of each.
- 12. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.),4.beta.]-7-[3-[3-hydroxy-4-(3-methylphenyl)-1-butenyl-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (fast moving isomer) or [1.beta.,2.alpha.(5Z),3.beta.(1E,3.beta.),4.beta.]-7-[3-[3-hydroxy-4-(3-methylphenyl)-1-butenyl-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (slow moving isomer) or methyl esters of each.
- 13. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.),4.beta.]-7-[3-(3-hydroxy-4-methyl-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (fast moving isomer) or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.),4.beta.]-7-[3-(3-hydroxy-4-methyl-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (slow moving isomer) or methyl esters of each.
- 14. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.),4.beta.]-7-[3-[3-hydroxy-3-(1-methylcyclohexyl)-1-propenyl]-7-oxabicyclo[2.2.1]hept-2-yl-5-heptenoic acid (fast moving isomer) or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-[3-[3-hydroxy-3-(1-methylcyclohexyl)-1-propenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (slow moving isomer) or methyl esters of each.
- 15. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.),4.beta.]-7-[3-[3-hydroxy-4-(4-methylphenyl)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (fast moving isomer) or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-[3-[3-hydroxy-4-(4-methylphenyl)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (slow moving isomer) or methyl esters of each.
- 16. The composition as defined in claim 1 wherein the compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.,4.alpha.),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-hexenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (fast moving isomer A) or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.,4.beta.),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-hexenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (fast moving isomer B) or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-heptenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (slow moving isomer) or methyl esters of each.
- 17. A method of inhibiting platelet aggregation which comprises administering to a mammalian host an effective amount of a compound having the structural formula ##STR60## and including all stereoisomers thereof; wherein
- A and B may be the same or different and A is CH.dbd.CH or (CH.sub.2).sub.2,
- B is CH.dbd.CH, C.tbd.C, or (CH.sub.2).sub.2 ; m is 1 to 8;
- X is OH; ##STR61## CO.sub.2 R.sup.1 wherein R.sup.1 is H or lower alkyl; or ##STR62## wherein Z is H, lower alkyl, or aryl, SO.sub.2 --Q (wherein Q is lower alkyl or aryl), ##STR63## or OR.sup.2 wherein R.sup.2 is H; Y is aryl-lower alkyl; alkenyl containing 3 to 6 carbons; alkynyl containing 3 to 6 carbons; pyridyl, pyridyl-lower alkyl; pyridyl containing one or two halogen or lower alkyl substituents; thienyl; thienylalkyl; thienyl containing one or two halogen or lower alkyl substituents; cycloalkyl; cycloalkyl containing one or two halogen, lower alkyl or lower alkoxy groups on the ring; cycloalkylalkyl, cycloalkylalkyl containing one or two halogen, lower alkyl or lower alkoxy groups on the ring; or phenoxymethyl; wherein lower alkyl or alkyl by itself or as part of another group contains 1 to 12 carbons, aryl by itself or as part of another group contains 6 to 10 carbons in the ring portion, and cycloalkyl by itself or as part of another group contains 3 to 12 carbons in the ring portion;
- and represents a single bond or double bond with the proviso that where represents a double bond, A is CH.dbd.CH and B is CH.dbd.CH or (CH.sub.2).sub.2 and Y is other than alkenyl or alkynyl or a pharmaceutically acceptable salt thereof.
- 18. A method of inhibiting broncho-constriction, which comprises administering to the circulatory system of a mammalian host an effective amount of a compound having the structural formula ##STR64## and including all stereoisomers thereof; wherein
- A and B may be the same or different and A is CH.dbd.CH or (CH.sub.2).sub.2,
- B is CH.dbd.CH, C.tbd.C, or (CH.sub.2).sub.2 ; m is 1 to 8;
- X is OH; ##STR65## CO.sub.2 R.sup.1 wherein R.sup.1 is H or lower alkyl; or ##STR66## wherein Z is H, lower alkyl, or aryl, SO.sub.2 --Q (wherein Q is lower alkyl or aryl), ##STR67## or OR.sup.2 wherein R.sup.2 is H; Y is lower alkyl provided at least one of A and B are other than CH.dbd.CH and X is other than CO.sub.2 R.sup.1, OH or ##STR68## aryl-lower alkyl; alkenyl containing 3 to 6 carbons; alkynyl containing 3 to 6 carbons; phenyl; phenyl including a lower alkyl, halogen or lower alkoxy substituent; naphthyl; naphthyl including a lower alkyl, halogen or lower alkoxy substituent; pyridyl, pyridyl-lower alkyl; pyridyl containing one or two halogen or lower alkyl substituents; thienyl; theinylalkyl; thienyl containing one or two halogen or lower alkyl substituents; cycloalkyl; cycloalkyl containing one or two halogen, lower alkyl or lower alkoxy groups on the ring; cycloalkylalkyl, cycloalkylalkyl containing one or two halogen, lower alkyl or lower alkoxy groups on the ring; or phenoxymethyl; wherein lower alkyl or alkyl by itself or as part of another group contains 1 to 12 carbons, aryl by itself or as part of another group contains 6 to 10 carbons in the ring portion, and cycloalkyl by itself or as part of another group contains 3 to 12 carbons in the ring portion;
- and represents a single bond or double bond with the proviso that where represents a double bond, A is CH.dbd.CH and B is CH.dbd.CH or (CH.sub.2).sub.2 and Y is other than alkenyl or alkynyl or a pharmaceutically acceptable salt thereof.
- 19. The method as defined in claim 18 wherein said compound is administered in an amount within the range of from about 1 to about 100 mg/kg.
REFERENCE TO OTHER APPLICATIONS
This is a division of application Ser. No. 378,547, filed May 17, 1982, which is a continuation-in-part of application Ser. No. 319,511, filed Nov. 9, 1981 now abandoned.
US Referenced Citations (6)
Non-Patent Literature Citations (1)
Entry |
Eggelte et al., J. C. S. Perkins I, 980, (1978). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
378547 |
May 1982 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
319511 |
Nov 1981 |
|